Top Stories
The company said Livsayis becomes the first and only approved siRNA therapy in generalised myasthenia gravis (gMG).
The companies will combine clinical trial findings with real-world patient data to investigate treatment outcomes, including measures of health beyond weight loss.
The investment was co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures with participation from Eli Lilly and other existing investors.
The MIT spinout says six of the world's 20 largest drugmakers have partnered with it to access its biomolecular AI models.
Preliminary Phase III data from the ADEPT programme presented at CTAD come as the company awaits pivotal readouts next year.
Conference News
Physicians see a niche for Boehringer Ingelheim and Zealand Pharma's survodutide among patients with obesity intolerant to marketed GLP-1 receptor agonists, though they seem doubtful that the glucagon/GLP-1 agonist can challenge established rivals.
New real-world evidence data from AMBAR® describe cognitive outcomes observed over 18 months in patients who underwent therapeutic plasma exchange (TPE) with albumin replacement in a real-world observ...
Drug Development Leaders Share RAS Findings at Global SymposiumFORT MYERS, Fla., Nov. 18, 2026 /PRNewswire/ -- Studies of emerging approaches to targeting RAS mutations, including two first-in-human c...
NEWPORT BEACH, CA, UNITED STATES, November 18, 2026 /EINPresswire.com/ -- Regeneration Biomedical, Inc., a clinical-stage biotechnology company developing regenerative therapies for neurodegenerative ...
Immuto’s structural surfaceomics platform reveals a distinct structural landscape on patient-derived KRAS-mutant colorectal cancer models compared to healthy colon organoidsCAMBRIDGE, Mass.--(BUSINESS...




